Medindia
Medindia LOGIN REGISTER
Advertisement

Adelson Medical Research Foundation Funds Research Initiative Focused on Multiple Myeloma

Tuesday, February 6, 2018 Cancer News
Advertisement
Foundation's open and highly integrated collaborative model brings together multi-disciplinary, multi-institutional scientific teams to address major unmet medical needs in oncology and neurology.
Advertisement

NEEDHAM, Mass., Feb. 5, 2018 /PRNewswire/ -- The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private foundation funding collaborative translational science, announced today the launch of the Adelson Program in Multiple Myeloma Research (APMMR). These three-year awards will help support seven biomedical researchers conducting translational research in multiple myeloma at four leading academic institutions across the U.S.
Advertisement

"Our foundation emphasizes the translation of discovery science to clinically applicable technologies in a quick and efficient manner," said Dr. Miriam Adelson, Trustee and Executive Director of the Foundation. Dr. Adelson is a dedicated physician-scientist who oversees clinics for the treatment of addictive diseases in Las Vegas and Tel Aviv. "AMRF encourages teams of renowned scientists across multiple institutions to collaboratively pursue significant research goals rather than incremental progress," noted Sheldon G. Adelson, Trustee of the Foundation and Chairman of the Board and Chief Executive Officer of Las Vegas Sands Corp.

"The APMMR is poised to have a significant impact on therapeutic advancements in an effort to treat and potentially cure multiple myeloma," explained Dr. Kristian Hedstrom, Chief Science Officer of AMRF. "Through AMRF's model of collaboration, this team of world class investigators will pursue novel interventions at all stages of this disease using some of the most cutting edge technologies available."

The research team will be led by Drs. Kenneth Anderson and Robert Orlowski. Dr Kenneth Anderson, MD is the chief of the Division of Hematologic Neoplasia, director of the Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber Cancer Institute and Kraft Family Professor of Medicine at Harvard Medical School. Dr. Robert Orlowski, MD, PhD is Department Chair ad interim, Florence Maude Thomas Cancer Research Professor, and Professor in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. They are joined by their colleagues Drs. Irene Ghobrial, MD and Benjamin Ebert, MD, PhD of Dana-Farber Cancer Institute, Dr. Elisabet Manasanch, MD of MD Anderson Cancer Center, Dr. Peter Kuhn, PhD of the University of Southern California, and Gad Getz, PhD of the Broad Institute.

The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, established in 2006, is a private foundation committed to a model of open and highly integrated collaboration among outstanding investigators who participate in goal-directed basic and clinical research to prevent, reduce or eliminate disabling and life-threatening illness. The Foundation creates a culture of scientific discovery, evaluation, and clinical application directed by the experiences of scientists who are not bound by searching for the cure of any single disease.

For additional information on the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, please visit http://www.adelsonfoundation.org/amrfphil.html

Media Contact:  Dr. Kristian Hedstrom Chief Science Officer Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (781) 972-5900 [email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/adelson-medical-research-foundation-funds-research-initiative-focused-on-multiple-myeloma-300593684.html

SOURCE Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

Sponsored Post and Backlink Submission


Latest Press Release on Cancer News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close